Bahrain vs Kuwait: HIV/AIDS deaths averted by antiretroviral therapy
Bahrain
20.62 deaths
in 2024
Kuwait
27 deaths
in 2022
Bahrain rank
147th
Kuwait rank
144th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bahrain
- Kuwait
How they compare
Kuwait currently reports 27 deaths against 20.62 deaths in Bahrain, a difference of 6.38 deaths.
That makes Kuwait's figure about 1.3 times Bahrain's.
The two have swapped places 2 times across 33 shared years of data; in 1990 it was Kuwait ahead.
Bahrain ranks 147th and Kuwait ranks 144th of 157 countries.
Kuwait has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bahrain | Kuwait | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 1.5 deaths | 1.5 deaths | Kuwait |
| 2000s | 3.99 deaths | 6.3 deaths | 2.31 deaths | Kuwait |
| 2010s | 7.14 deaths | 15.7 deaths | 8.56 deaths | Kuwait |
| 2020s | 15.97 deaths | 25.33 deaths | 9.37 deaths | Kuwait |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bahrain or Kuwait?
- Kuwait, at 27 deaths against 20.62 deaths in Bahrain as of 2022.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bahrain and Kuwait?
- 6.38 deaths, with Kuwait ahead.
- How many years of comparable data are there for Bahrain and Kuwait?
- 33 years are reported by both, from 1990 to 2022.
- How do Bahrain and Kuwait rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bahrain ranks 147th and Kuwait ranks 144th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.